242 related articles for article (PubMed ID: 31805626)
1. Deregulation of the Histone Lysine-Specific Demethylase 1 Is Involved in Human Hepatocellular Carcinoma.
Kim S; Bolatkan A; Kaneko S; Ikawa N; Asada K; Komatsu M; Hayami S; Ojima H; Abe N; Yamaue H; Hamamoto R
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31805626
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients.
Zhao ZK; Yu HF; Wang DR; Dong P; Chen L; Wu WG; Ding WJ; Liu YB
World J Gastroenterol; 2012 Dec; 18(45):6651-6. PubMed ID: 23236241
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma.
Zhao ZK; Dong P; Gu J; Chen L; Zhuang M; Lu WJ; Wang DR; Liu YB
Tumour Biol; 2013 Feb; 34(1):173-80. PubMed ID: 23015317
[TBL] [Abstract][Full Text] [Related]
4. LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-like Cells.
Liu C; Liu L; Chen X; Cheng J; Zhang H; Zhang C; Shan J; Shen J; Qian C
Cancer Res; 2018 Feb; 78(4):938-949. PubMed ID: 29259010
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression.
Agboyibor C; Dong J; Effah CY; Drokow EK; Pervaiz W; Li D; Kang L; Ma X; Li J; Liu Z; Liu HM
Cancer Control; 2021; 28():10732748211051557. PubMed ID: 34802287
[TBL] [Abstract][Full Text] [Related]
8. High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer.
Yuan C; Li Z; Qi B; Zhang W; Cheng J; Wang Y
J Oral Pathol Med; 2015 Feb; 44(2):159-65. PubMed ID: 25040359
[TBL] [Abstract][Full Text] [Related]
9. H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1.
Magerl C; Ellinger J; Braunschweig T; Kremmer E; Koch LK; Höller T; Büttner R; Lüscher B; Gütgemann I
Hum Pathol; 2010 Feb; 41(2):181-9. PubMed ID: 19896696
[TBL] [Abstract][Full Text] [Related]
10. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
[TBL] [Abstract][Full Text] [Related]
11. The coordination between ZNF217 and LSD1 contributes to hepatocellular carcinoma progress and is negatively regulated by miR-101.
Si W; Zhao Y; Zhou J; Zhang Q; Zhang Y
Exp Cell Res; 2019 Jun; 379(1):1-10. PubMed ID: 30898548
[TBL] [Abstract][Full Text] [Related]
12. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686.
Wu BH; Chen H; Cai CM; Fang JZ; Wu CC; Huang LY; Wang L; Han ZG
Oncotarget; 2016 Feb; 7(6):6847-63. PubMed ID: 26760772
[TBL] [Abstract][Full Text] [Related]
14. LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC.
Ma L; Xu A; Kang L; Cong R; Fan Z; Zhu X; Huo N; Liu W; Xue C; Ji Q; Li W; Chu Z; Kang X; Wang Y; Sun Z; Han Y; Liu H; Gao X; Han J; You H; Zhao C; Xu X
Hepatology; 2021 Dec; 74(6):3213-3234. PubMed ID: 34322883
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
[TBL] [Abstract][Full Text] [Related]
16. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
17. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Cao C; Vasilatos SN; Bhargava R; Fine JL; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2017 Jan; 36(1):133-145. PubMed ID: 27212032
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma.
Liu YD; Dai M; Yang SS; Xiao M; Meng FL; Chen XW
Int J Gynecol Cancer; 2015 Oct; 25(8):1453-60. PubMed ID: 26166558
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
20. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
